Publications by authors named "J Mark Madison"
Clinical tools that can aid in the diagnostic differentiation of juvenile dermatomyositis from muscular dystrophy.
View Article and Find Full Text PDFArticle Synopsis
- - Leptospirosis, a disease caused by bacteria prevalent mostly in tropical areas, is transmitted through contact with infected rat urine or contaminated environments, with brown rats being key urban reservoirs.
- - A study conducted in Boston from 2016-2022 involved analyzing DNA from 328 rat kidney samples, revealing that 59 rats were positive for leptospirosis and indicating significant genetic structure and limited dispersal among rat populations.
- - The researchers discovered distinct genetic clades of the bacteria linked to specific rat groups, suggesting that rat movement influences the spread of leptospirosis, and indicated a connection between the disease in humans and urban rat populations based on genomic analysis.
Article Synopsis
- Neutrophil hyperactivity and NET release are key factors in the autoimmune disease antiphospholipid syndrome (APS).
- Research shows that neutrophils from APS patients have a higher reliance on glycolysis compared to those from healthy individuals, particularly in cases linked to microvascular disease.
- Inhibiting glycolysis or the pentose phosphate pathway (PPP) not only reduces NET release and reactive oxygen species production in neutrophils but also significantly decreases thrombosis in mice models of APS.
Our study aimed to evaluate the presence, clinical associations, and potential mechanistic roles of non-criteria antiphospholipid antibodies (aPL) and circulating calprotectin, a highly stable marker of neutrophil extracellular trap release (NETosis), in pediatric APS patients. We found that 79% of pediatric APS patients had at least one non-criteria aPL at moderate-to-high titer. Univariate logistic regression demonstrated that positive anti-beta-2 glycoprotein I domain 1 (anti-D1) IgG (p = 0.
View Article and Find Full Text PDFIn this issue of , Maher et al. report the results of a randomized, controlled, 22-day treatment crossover trial comparing the antitussive effect of extended-release nalbuphine, an opioid agonist-antagonist, with placebo in a cohort of patients with definite or probable idiopathic pulmonary fibrosis (IPF). In this small, short-term trial of 38 evaluable patients, the active drug was associated with a 75.
View Article and Find Full Text PDF